Abstract N-methyl-d-aspartate (NMDA) receptor (NMDAR) hypofunction plays a key role in
pathophysiology of schizophrenia. Since NMDAR hypofunction has also been reported in …

Traditional pharmacological treatments for depression have a delayed therapeutic onset,
ranging from several weeks to months, and there is a high percentage of individuals who …

Ketamine, functioning as a channel blocker of the excitatory glutamate-gated N-methyl-d-
aspartate (NMDA) receptors, displays compelling fast-acting and sustained antidepressant …

NMDA receptors (NMDARs) play subunit-specific roles in synaptic function and are
implicated in neuropsychiatric and neurodegenerative disorders. However, the in vivo …

Developing cortical GABAergic interneurons rely on genetic programs, neuronal activity, and
environmental cues to construct inhibitory circuits during early postnatal development …

The N-methyl-d-aspartate receptor hypofunction is one of the most prevalent models of
schizophrenia. For example, healthy subjects treated with uncompetitive N-methyl-d …

A growing body of evidence suggests glutamate excess in schizophrenia and that N-methyl-
d-aspartate receptor (NMDAR) hypofunction on γ-aminobutyric acid (GABA) interneurons …

The pharmacological modulation of glutamatergic neurotransmission to improve cognitive
function has been a focus of intensive research, particularly in relation to the cognitive …

Molecular imaging with positron emission tomography (PET) and single photon emission
computed tomography (SPECT) is a well-established and important in vivo technique to …

Approximately one-third of individuals with major depressive disorder are resistant to
conventional antidepressants (ie, monoamine-based therapies), and, even among …